Format

Send to

Choose Destination
J Immunol. 2018 Nov 15;201(10):3096-3105. doi: 10.4049/jimmunol.1701722. Epub 2018 Oct 15.

MAbTope: A Method for Improved Epitope Mapping.

Author information

1
Unité de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique, Université François Rabelais-Tours, CNRS, 37380 Nouzilly, France.
2
Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, TX 77030.
3
MAbSilico Société par Actions Simplifiée, Domaine de l'Orfrasière, 37380 Nouzilly, France.
4
Biology Department, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates.
5
Calcul Scientifique et Modélisation Orléans Tours, l'Unité de Formation et de Recherche Sciences et Techniques, Université François-Rabelais, 37041 Tours, France; and.
6
Centre Hospitalier Régional Universitaire de Tours, Université François-Rabelais de Tours, CNRS, UMR 7292, 37041 Tours, France.
7
Unité de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique, Université François Rabelais-Tours, CNRS, 37380 Nouzilly, France; Anne.poupon@inra.fr.

Abstract

Abs are very efficient drugs, ∼70 of them are already approved for medical use, over 500 are in clinical development, and many more are in preclinical development. One important step in the characterization and protection of a therapeutic Ab is the determination of its cognate epitope. The gold standard is the three-dimensional structure of the Ab/Ag complex by crystallography or nuclear magnetic resonance spectroscopy. However, it remains a tedious task, and its outcome is uncertain. We have developed MAbTope, a docking-based prediction method of the epitope associated with straightforward experimental validation procedures. We show that MAbTope predicts the correct epitope for each of 129 tested examples of Ab/Ag complexes of known structure. We further validated this method through the successful determination, and experimental validation (using human embryonic kidney cells 293), of the epitopes recognized by two therapeutic Abs targeting TNF-α: certolizumab and golimumab.

PMID:
30322966
DOI:
10.4049/jimmunol.1701722
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center